Oracle engineers caused days-long software outage at U.S. hospitals

Oracle engineers caused days-long software outage at U.S. hospitals


Larry Ellison, co-founder and executive chairman of Oracle Corp., speaks during the Oracle OpenWorld 2018 conference in San Francisco, California, U.S., on Monday, Oct. 22, 2018.

David Paul Morris | Bloomberg | Getty Images

Oracle engineers mistakenly triggered a five-day software outage at a number of Community Health Systems hospitals, causing the facilities to temporarily return to paper-based patient records.

CHS told CNBC that the outage involving Oracle Health, the company’s electronic health record (EHR) system, affected “several” hospitals, leading them to activate “downtime procedures.” Trade publication Becker’s Hospital Review reported that 45 hospitals were hit.

The outage began on April 23, after engineers conducting maintenance work mistakenly deleted critical storage connected to a key database, a CHS spokesperson said in a statement. The outage was resolved on Monday, and was not related to a cyberattack or other security incident.

CHS is based in Tennessee and includes 72 hospitals in 14 states, according to the medical system’s website.

“Despite this being a major outage, our hospitals were able to maintain services with no material impact,” the spokesperson said. “We are proud of our clinical and support teams who worked through the multi-day outage with professionalism and a commitment to delivering high-quality, safe care for patients.” 

Stock Chart IconStock chart icon

hide content

Oracle stock this year

Oracle didn’t immediately respond to CNBC’s request for comment.

An EHR is a digital version of a patient’s medical history that’s updated by doctors and nurses. It’s crucial software within the U.S. health-care system, and outages can cause serious disruptions to patient care. Oracle acquired EHR vendor Cerner in 2022 for $28.3 billion, becoming the second-biggest player in the market, behind Epic Systems.

Now that Oracle’s systems are back online, CHS said that the impacted hospitals are working to “re-establish full functionality and return to normal operations and procedures.”

Oracle’s CHS error comes weeks after the company’s federal electronic health record experienced a nationwide outage. Oracle has struggled with a thorny, years-long EHR rollout with the Department of Veterans Affairs, marred by patient safety concerns. The agency launched a strategic review of Cerner in 2021, before Oracle’s acquisition, and it temporarily paused deployment of the software in 2023.

WATCH: Interview with Oracle CEO Safra Catz

Oracle CEO Safra Catz: Being number one is very important



Source

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market
Health

2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market

The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. […]

Read More
Healthy Returns: What to expect from pharma at the JPM conference
Health

Healthy Returns: What to expect from pharma at the JPM conference

Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of Commerce Howard Lutnick listen while U.S. President Donald Trump announces a deal with Eli Lilly and Novo Nordisk on to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White […]

Read More
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year
Health

A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year

Europe’s best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion. Abivax, the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn’s disease, saw shares rocket 1,681% last year, far outpacing the Stoxx 600 […]

Read More